The analyst's focus is Acadia, so this would be estimated peak sales of trofinetide in Rett syndrome in North America.
Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference, page-69
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.02 |
Change
-0.705(3.40%) |
Mkt cap ! $2.570B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $2.697M | 134.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 164 | $20.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.02 | 178 | 7 |
View Market Depth
| Last trade - 13.11pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |